Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Data in a Mice Model of Parkinson’s disease from Its DJ-1 Protein Targeting Therapeutic Program at the Neuro4D Conference in Mainz, Germany
Please be advised that the Corporate and Investor Relations personnel are not licensed for the sale or purchase of our common stock, and their phone numbers should not be used for placing orders for any share purchases. You should contact your individual broker if you wish to discuss your investment options and decisions.
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases.
Blue Sky Exemption
Cantabio Pharmaceuticals is listed in Mergent Manuals and News Reports™ and the company’s data, as well as news and financial statements, are accessible via Mergent’s online and print products. The Mergent Industrial Manual and News Reports™ is a recognized securities manual in 39 states for purposes of Blue Sky Manual Exemption. The company’s listing and further information is available here: www.mergent.com
Sign up for email updates
Be the first to receive breaking newsSign Up